Bioequivalence Study of Ivermectin From Revemact 6 mg Tablets (Man. by EVA Pharma for Horus for Pharmaceutical Industries, Egypt) and Stromectol 2*3 mg Tablets (Merck Sharp & Dohme B.V., Haarlem, The Netherlands)

NCT04854460 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Revemact
DRUG: Stromectol (first dose)
DRUG: Stromectol (second dose)

Sponsor

Genuine Research Center, Egypt

Collaborators

[object Object]